Stock Events

Stock Events

Fennec Pharmaceuticals 

€10.70
14
+€0.00+0% 17:32 Today

Statistics

Day High
10.7
Day Low
10.1
52W High
10.7
52W Low
4.16
Volume
-
Avg. Volume
-
Mkt Cap
375.22M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q1 2026
Q2 2026
Next
-0.04
0
0.04
0.09
Expected EPS
0.08602
Actual EPS
N/A

Financials

-21.67%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
38.64MRevenue
-8.37MNet Income

Analyst Ratings

11.89Average Price Target
The highest estimate is 13.66.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RV41.STU. It's not an investment recommendation.
NVIDIA
2
NVDA
Eton Pharmaceuticals
2
ETON

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global pharmaceutical company that competes with Fennec Pharmaceuticals in the oncology sector, particularly in developing treatments for cancer-related conditions.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is a leading pharmaceutical company that develops cancer therapies, directly competing with Fennec Pharmaceuticals' focus on oncology.
Novartis
NVS
Mkt Cap292.35B
Novartis AG competes in the pharmaceutical industry by offering a wide range of oncology drugs, which puts it in direct competition with Fennec Pharmaceuticals.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division Janssen, develops and markets oncology drugs, competing with Fennec Pharmaceuticals in the cancer treatment space.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb is involved in the discovery, development, and marketing of cancer drugs, making it a competitor to Fennec Pharmaceuticals in the oncology field.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, with its strong portfolio in oncology, competes with Fennec Pharmaceuticals in developing and marketing cancer treatments.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC has a significant presence in the oncology sector, developing treatments that compete with Fennec Pharmaceuticals' cancer-focused therapies.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. is known for its innovative therapies in oncology, among other areas, competing with Fennec Pharmaceuticals in the cancer treatment market.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. focuses on human therapeutics, including oncology, which puts it in competition with Fennec Pharmaceuticals in the development of cancer treatments.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. is involved in the development of oncology drugs, competing with Fennec Pharmaceuticals in the cancer therapy market.

About

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Show more...
CEO
Jeffrey S. Hackman
Employees
35
Country
Canada
ISIN
CA31447P1009
WKN
000A12A5F

Listings

STU
DE
RV41.STU
MU
DE
RV41.MU
F
DE
RV41.F
XNAS
US
FENC

0 Comments

Share your thoughts

FAQ

What is Fennec Pharmaceuticals stock price today?▼
The current price of RV41.STU is €10.70 EUR — it has increased by +0% in the past 24 hours. Watch Fennec Pharmaceuticals stock price performance more closely on the chart.
What is Fennec Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Fennec Pharmaceuticals stocks are traded under the ticker RV41.STU.
Is Fennec Pharmaceuticals stock price growing?▼
RV41.STU stock has risen by +11.58% compared to the previous week, the month change is a +21.84% rise, over the last year Fennec Pharmaceuticals has showed a +41.33% increase.
What is Fennec Pharmaceuticals market cap?▼
Today Fennec Pharmaceuticals has the market capitalization of 375.22M
When is the next Fennec Pharmaceuticals earnings date?▼
Fennec Pharmaceuticals is going to release the next earnings report on November 05, 2026.
What were Fennec Pharmaceuticals earnings last quarter?▼
RV41.STU earnings for the last quarter are 0.04 EUR per share, whereas the estimation was 0.02 EUR resulting in a +150% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Fennec Pharmaceuticals revenue for the last year?▼
Fennec Pharmaceuticals revenue for the last year amounts to 38.64M EUR.
What is Fennec Pharmaceuticals net income for the last year?▼
RV41.STU net income for the last year is -8.37M EUR.
How many employees does Fennec Pharmaceuticals have?▼
As of September 04, 2026, the company has 35 employees.
In which sector is Fennec Pharmaceuticals located?▼
Fennec Pharmaceuticals operates in the Health & Wellness sector.
When did Fennec Pharmaceuticals complete a stock split?▼
Fennec Pharmaceuticals has not had any recent stock splits.
Where is Fennec Pharmaceuticals headquartered?▼
Fennec Pharmaceuticals is headquartered in RESEARCH TRIANGLE PARK, Canada.